Drug Trial Radar · NCT02618577
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2,608
Actual
Start
Feb 2016
Primary completion
Dec 31, 2022
Study completion Dec 31, 2022
Sponsor
- Lead sponsor
- Atrial Fibrillation NetworkAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
- First posted
- Dec 1, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be conducted in several European countries.
Conditions
- Atrial High Rate Episodes
Interventions
EdoxabanDrug
Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF
ASADrug
ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of Stroke, Systemic Embolism, or Cardiovascular DeathTime frame: 28 months
Locations
18 sites in 18 countries. Site status is shown where the registry gives one.
Several Sites
Multiple Locations, Austria
Several Sites
Multiple Locations, Belgium
Several
Multiple Locations, Bulgaria
Several
Multiple Locations, Czechia
Several
Multiple Locations, Denmark
Several
Multiple Locations, France
Several Sites
Multiple Locations, Germany
Several
Multiple Locations, Greece
Several
Multiple Locations, Hungary
Several
Multiple Locations, Italy
Several
Multiple Locations, Netherlands
Several
Multiple Locations, Poland
Several
Multiple Locations, Portugal
Several
Multiple Locations, Romania
Several
Multiple Locations, Spain
Several
Multiple Locations, Sweden
Several
Multiple Locations, Ukraine
Several
Multiple Locations, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.